Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Gains from Investment Securities (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Gains from Investment Securities for 9 consecutive years, with -$2.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 91400.0% to -$2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a 278.12% increase, with the full-year FY2025 number at $2.6 million, up 521.54% from a year prior.
  • Gains from Investment Securities was -$2.7 million for Q4 2025 at Akebia Therapeutics, down from $5.5 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $51.3 million in Q4 2022 to a low of -$11.0 million in Q3 2022.
  • A 5-year average of $1.1 million and a median of -$1.2 million in 2021 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 5519.98% in 2022, then tumbled 91400.0% in 2025.
  • Akebia Therapeutics' Gains from Investment Securities stood at -$946000.0 in 2021, then soared by 5519.98% to $51.3 million in 2022, then tumbled by 115.94% to -$8.2 million in 2023, then skyrocketed by 100.04% to $3000.0 in 2024, then crashed by 91400.0% to -$2.7 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Gains from Investment Securities are -$2.7 million (Q4 2025), $5.5 million (Q3 2025), and $52000.0 (Q2 2025).